CASE REPORT article
Front. Med.
Sec. Nuclear Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1569143
This article is part of the Research Topic25 Years of 21st Century MedicineView all 5 articles
Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review
Provisionally accepted
- 1Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 2Kaiyang People's Hospital, Guiyang, Guizhou Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Advanced prostate cancer (PCa) is still an incurable disease. Still, the field of PSMA-targeted radioligand therapy is developing rapidly and is playing an increasingly important role in the treatment of advanced Pca in the future. As an α -particle emitter, Ac-225 shows a potent killing ability for tumor cells due to its short range and high energy deposition in the tumor micrometastasis focus. However, the secondary myelofibrosis (SMF) associated with Ac-225-PSMA-617 treatment is a significant concern. We present a case of metastatic castration-resistant prostate cancer (mCRPC) who developed pancytopenia following the Ac-225-PSMA-617 treatment period, a bone marrow biopsy confirmed SMF and remained uncorrected after multiple component transfusions and symptomatic supportive therapy.Ac-225-PSMA-617 has demonstrated promising therapeutic efficacy in the management of advanced PCa; however, the potential risks associated with SMF necessitate careful consideration. Through comprehensive analysis of this clinical case and comparative evaluation with the existing literature, this study highlights the need to balance clinical benefit with increased vigilance for treatment-related adverse events.
Keywords: Ac-225-PSMA-617, Secondary myelofibrosis, metastatic castration-resistant prostate cancer, Radioligand Therapy, case repoort
Received: 31 Jan 2025; Accepted: 13 Jun 2025.
Copyright: © 2025 王, Tang, Liu, Xie, Li, Du and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tao Wu, Affiliated Hospital of Zunyi Medical University, Zunyi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.